Afrida Tabassum

Ms. Afrida Tabassum

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2026 in Neuroglia
Verified
Journal Article
Open access
PDF file
MAMd. Aktaruzzaman
Md. Aktaruzzaman
MAMd. Ahsan Abid
Md. Ahsan Abid
ARAsaduzzaman Rakib
Asaduzzaman Rakib
MIMd Sazzadul Islam
Md Sazzadul Islam
HDHumayra Afroz Dona
Humayra Afroz Dona
MRMd Obayed Raihan
Md Obayed Raihan
The coronavirus disease 2019 (COVID-19) pandemic has been associated with a wide range of neurological complications, among which persistent cognitive impairment and memory deficits are increasingly recognized as key symptoms of the post-acute sequelae of SARS-CoV-2 infection (PASC or long COVID). Although clinical and epidemiological studies have documented these symptoms across diverse patient populations, the underlying neurobiological mechanisms remain incompletely understood. Growing evidence from human studies, neuropathological analyses, and experimental models indicates that neuroimmune and inflammatory processes plays a central role in COVID-19-associated cognitive dysfunction. As the brain’s resident immune cells, microglia are vital for synaptic health, neuroplasticity, and memory, yet these processes may be compromised after SARS-CoV-2 infection. Systemic inflammation, blood–brain barrier (BBB) disruption, endothelial injury, and cytokine signaling can induce sustained microglial activation and priming, leading to inflammasome activation, complement-mediated synaptic remodeling, oxidative stress, and impaired hippocampal neurogenesis. These processes collectively disrupt neural circuits involved in learning and memory and may underlie the persistent “brain fog” reported by COVID-19 survivors. This review synthesizes clinical, biomarker, neuroimaging, and mechanistic evidence linking SARS-CoV-2 infection to microglia-mediated neuroinflammation and memory impairment. In contrast to prior reviews that broadly describe neuroinflammation in COVID-19, we integrate multidimensional evidence into a microglia-centric immunovascular framework that highlights converging pathogenic pathways underlying cognitive symptoms. We further discuss emerging biomarkers of glial activation and evaluate current and prospective therapeutic strategies targeting microglial and neuroimmune pathways. Understanding the role of microglial dysregulation in post-COVID cognitive impairment may facilitate the development of targeted interventions to mitigate long-term neurological consequences of COVID-19.

11 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
OBOmar Faruk Bhuiyan
Omar Faruk Bhuiyan
MHMuhammad Taki Hasan
Muhammad Taki Hasan
ATAfrida Tabassum
Afrida Tabassum
SASamiul Alam
Samiul Alam
SISamiha Islam
Samiha Islam
SNSyed Mohammed Nuruddin
Syed Mohammed Nuruddin
Respiratory tract cancers (RTCs), including lung, laryngeal, nasopharyngeal, and tracheal cancers, are among the most common cancer types. These cancers show difficulties in the case of early diagnosis and treatment monitoring. The microbiome, the community of microbes living in a single area of the body, is associated with cancer and offers potential for developing non-invasive diagnostic tools and probiotic therapies. Microbiome dysbiosis affects both the tumor and the immune microenvironment. The major pathways of RTCs, including EGFR, ALK, KRAS, STAT3, WNT, etc., are affected by the dysbiosis that occurs during cancer progression. Several microbial species have also been associated with treatment outcomes of immune checkpoint inhibitors (ICIs), chemotherapy, and anti-PD-1 therapy. Microbes such as Alistipes indistinctus, Alistipes shahii, Barnesiella viscericola, Streptococcus salivarius, Parabacteroides, and Faecalibacterium, along with genera like Bifidobacterium, Collinsella, Veillonella, and families/orders like Actinomycetales, Odoribacteraceae, and Selenomonadales, have shown positive associations with overall survival, progression-free survival, and improved treatment responses. Conventional biomarkers for RTCs have greatly improved diagnosis and monitoring. Still, they suffer from limitations such as low sensitivity in early-stage, intrusive sample procedures, and a lack of specificity. In contrast, gut, airway, and oral microbiota have emerged as promising non-invasive biomarkers with established associations to cancer progression, metabolic pathways, immune responses, and treatment monitoring. Moreover, non-invasive sampling methods like stool, sputum, and oral swabs offer improved patient comfort and early detection opportunities. In this mini review, we explore global research on human microbiomes as potential diagnostic or therapeutic biomarkers and their associations with RTCs.